October 15, 2018 12:32 AM EDTUpdated 04:09 AM
People
China

#BI­IS18 In­ter­view: Or­biMed Asi­a's Jonathan Wang on his up­bring­ing, de­cid­ing against a con­sult­ing ca­reer, blunt ad­vice for Chi­nese en­tre­pre­neurs, and more

Arsalan Arif

Founder

Next week we kick off the first an­nu­al US-Chi­na Bio­phar­ma In­no­va­tion and In­vest­ment Sum­mit in Shang­hai, fea­tur­ing some of the lead­ing transpa­cif­ic news­mak­ers in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Pfiz­er’s prostate can­cer da­ta leak shows promis­ing re­sults in ear­ly-stage study

No­var­tis re­turns for its an­ti­co­ag­u­lant in up to $3.1B buy of Black­stone’s An­thos

What will phar­ma's share buy­back shop­ping spree mean for M&A?

Ver­tex op­er­a­tions chief Stu­art Ar­buck­le to re­tire

Up­dat­ed: Judge halts NIH cuts na­tion­wide af­ter groups, 22 states sue

sponsored

Re­duc­ing risk in drug de­vel­op­ment: The im­por­tance of val­i­dat­ed MRD test­ing in lym­phoid can­cers

A service from the Financial Times